E09241

Overview

E09241 is an orally active osteoclastogenesis inhibitor. E09241 reduces the RANKL-induced expression of NFATc1 and MMP-9 by activating Wnt/β-catenin . E09241 increases the OPG/RANKL ratio by upregulating OPG expression, inhibits bone resorption, promotes bone formation and prevents ovariectomy-related bone loss. E09241 can be used in the research of osteoporosis.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Mineral Metabolism | Products > Disease Areas > Osteoporosis | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > RANKL/RANK | Products > Signaling Pathways > Wnt | Products > Signaling Pathways > β-catenin | Products > Signaling Pathways > Nuclear Factor of activated T Cells (NFAT) | Products > Signaling Pathways > MMP

Product Information

• Catalog No.: HY-W185542
• CAS No.: 1043110-13-9
• Molecular Formula: C11H9ClN2O2
• Molecular Weight: 236.66
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source